Journal Watch · Journal of Controlled Release · 2026
Pharmaceutical cocrystals beyond enteral drug delivery: from concept to translation.
We believe the insights gained herein offer scientists a guide for formulating non-enteral cocrystal dosage forms in a judicious and effective manner, with the ultimate goal of accelerate the progress of next generation cocrystals for more complicated medical conditions.
TL;DR
We believe the insights gained herein offer scientists a guide for formulating non-enteral cocrystal dosage forms in a judicious and effective manner, with the ultimate goal of accelerate the progress of next generation cocrystals for more complicated medical conditions.
Key findings
- The critical knowledge gaps that discourage scientists from initiating research in cocrystal beyond enteral use will also be clarified.
- Finally, future perspectives will be provided to propose innovative approaches to close the knowledge gaps.
- We believe the insights gained herein offer scientists a guide for formulating non-enteral cocrystal dosage forms in a judicious and effective manner, with the ultimate goal of accelerate the progress of next generation cocrystals for more complicated medical conditions.
What they did
The stagnation in clinical translation of cocrystal beyond enteral applications, particularly in pulmonary, nasal, and topical delivery, hinders the full realization of its potential for targeted therapy delivery to specific disease sites. Hence, this review aims to explore the feasibility of developing sophisticated non-enteral cocrystal formulations within the confines of our current expertise and understanding. It will begin with an overview of the updated landscape in cocrystal development, followed by a discussion on the importance and merits of redirecting attention towards non-enteral preparation of cocrystals.
Full abstract (original)
Background: Over the past decade, significant research efforts have been dedicated to the development of oral cocrystal dosage forms, giving rise to the launch of groundbreaking medications such as Entresto® and Steglatro®. Numerous scholars have thoroughly examined the rational design and fabrication of pharmaceutical cocrystals, as well as their potential for property enhancement. However, the field pertaining to cocrystal development beyond enteral applications has rarely been comprehensively reviewed, despite such an untapped niche could represent a significant scientific leap to revolutionize the current cocrystal research domain.
What they did: The stagnation in clinical translation of cocrystal beyond enteral applications, particularly in pulmonary, nasal, and topical delivery, hinders the full realization of its potential for targeted therapy delivery to specific disease sites. Hence, this review aims to explore the feasibility of developing sophisticated non-enteral cocrystal formulations within the confines of our current expertise and understanding. It will begin with an overview of the updated landscape in cocrystal development, followed by a discussion on the importance and merits of redirecting attention towards non-enteral preparation of cocrystals.
Results & conclusions: The critical knowledge gaps that discourage scientists from initiating research in cocrystal beyond enteral use will also be clarified. Finally, future perspectives will be provided to propose innovative approaches to close the knowledge gaps. We believe the insights gained herein offer scientists a guide for formulating non-enteral cocrystal dosage forms in a judicious and effective manner, with the ultimate goal of accelerate the progress of next generation cocrystals for more complicated medical conditions.
Abstract © the authors / Journal of Controlled Release (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.jconrel.2026.115277 · PubMed 42632537.
Why it matters for pharma & biotech
- Relevant to Pharmacology & Drug Discovery teams tracking Journal of Controlled Release for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Journal of Controlled Release study find?
We believe the insights gained herein offer scientists a guide for formulating non-enteral cocrystal dosage forms in a judicious and effective manner, with the ultimate goal of accelerate the progress of next generation cocrystals for more complicated medical conditions.
What type of study is this?
It is a review / perspective, published in Journal of Controlled Release in 2026. The stagnation in clinical translation of cocrystal beyond enteral applications, particularly in pulmonary, nasal, and topical delivery, hinders the full realization of its potential for targeted therapy delivery to specific disease sites.
Where can I read the original paper?
The original is at the publisher via DOI 10.1016/j.jconrel.2026.115277. PubMed ID: 42632537. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/pharmaceutical-cocrystals-beyond-enteral-drug-delivery-from-concept-to-t-115277/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides